Sign in

    Tony Wible

    Managing Director and Senior Sell Side Analyst at Drexel Hamilton LLC

    Tony Wible is a Managing Director and Senior Sell Side Analyst at Drexel Hamilton LLC, specializing in Technology and Media, with a particular focus on the Media and Entertainment sectors. He has provided research coverage on notable companies such as Netflix, Regencell Bioscience Holdings, and participated in high-profile deals including the PayPal IPO, consistently delivering impactful investment calls that helped generate billions in market value. Wible began his career with Citigroup Investment Research, spent seven years at Janney Montgomery Scott covering media, and joined Drexel Hamilton in 2015. He is a CFA Charterholder, contributed to the creation of the Series 86 and 87 Wall Street analyst exams, was named a Top 10 Forbes stock picker, and is recognized by platforms such as StarMine and Institutional Investor.

    Tony Wible's questions to Regencell Bioscience Holdings (RGC) leadership

    Tony Wible's questions to Regencell Bioscience Holdings (RGC) leadership • Q2 2016

    Question

    Tony Wible of Drexel Hamilton LLC questioned the economic structure of concession pre-sales through Atom Tickets and sought confirmation on whether film rent fluctuations were due to slate mix rather than changes in studio deals. He also asked for the maturity date and interest rate terms of the senior credit facility.

    Answer

    Chairman & CEO Amy E. Miles described the Atom Tickets deal as 'very favorable' but declined to disclose specifics for competitive reasons. Executive VP, CFO & Treasurer David H. Ownby confirmed that film rent changes were entirely due to the film slate mix and not new studio agreements. He also stated the senior credit facility expires in 2022 and carries a rate of LIBOR plus 2.75% after a recent 25 basis point reduction.

    Ask Fintool Equity Research AI